Review Article
Challenges in Immunotherapy Presented by the Glioblastoma Multiforme Microenvironment
Table 5
Selected clinical trials using autologous tumor cells (ATCs).
| | Reference | Patients | Immunologic response | Clinical response |
| | [174] |
recurrent GBM | Local skin reaction | Median survival: 46 weeks | | [175] |
GBM | Delayed-type hypersensitivity, increased memory T cells, increased CD8+ T cells in recurrent tumors | Median progression free survival: 40 weeks, median survival 100 weeks | | [176] |
GBM | — | CR: 1, PR: 1, minor response: 2, median survival: 10.7 mo |
|
|
